Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016 Uncertainties

NEW YORK, NY / ACCESSWIRE / March 15, 2017 / Biotech stocks are among the most volatile sectors on the market as much of their stock price is directly connected to the success or failure of their niche drug products. Research and development costs and meeting FDA approval requirements often require the company to either have reliable investors who are willing to weather the decisions of the FDA testing cycle or have a large cash reserve when starting the company.

RDI Initiates
Coverage:

Antares Pharma Inc. https://ub.rdinvesting.com/news/?ticker=ATRS

Nivalis Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=NVLS

Antares Pharma saw its stock rise more than 4 percent, as it closed at $2.59 a share, up 10 cents. This, despite the company reporting a 3 cent per share loss in earnings for the 4th quarter. Revenue in the fourth quarter increased by 20 percent to $14.2 million from $11.8 million revenue in the same reporting period one year ago. Antares stock has been on a steady rise for the past year. The company develops and manufactures pressure-assisted injector devices that allow patients to self-inject prescription drugs. The devices have options for both needle and needleless injections. The company’s current project is the development of a single dose auto-injector for OTREXUP (methotrexate).

Access RDI’s Antares Pharma Research Report at: https://ub.rdinvesting.com/news/?ticker=ATRS

Nivalis Therapeutics ticked up 4 cents a share Tuesday, to close at $2.96 a share, up 1.34 percent. As it reported failed Phase 2 trial of its N9115 drug candidate for the treatment of cystic fibrosis, Nivalis stock fell off the shelf in November 28, 2016 when its shares fell to $2.17 a share after a $6.17 per share price the day before. The company was created to discover and develop products for patients with cystic fibrosis in the United States. Its lead product candidate is N91115, also known as cavosonstat. Nivalis hasn’t started generating any revenue and the company has reported net loss of $31.9 million and $22.9 million for year 2016 and 2015 respectively. The company has no debt on its books and a $61 million cash reserve as on December 31st, 2016. As the company is actively looking for strategic alternatives to maximize shareholders value, this makes the company a possible takeover candidate and considering the market for its lead product targets a potential population of 100,000 patients, hardly enough to sustain the company over the long term given the existing competition. Yet when taking into consideration the company’s significant drop in price from what it was just 6 months ago, there is likely more than meets the eye to this company’s present stock value and overall future.

Access RDI’s Nivalis Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=NVLS

Our Actionable Research on Antares Pharma Inc. (NASDAQ: ATRS) and Nivalis Therapeutics Inc. (NASDAQ: NVLS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457310